DRMA: Dermata Company Value to Net Income

Corporate emblem and logo of Dermata (DRMA)

Dermata Therapeutics (DRMA) price action reflects a current PE multiple of -0.30, with the company's revenues expected to be driven by the market launch of innovative treatments for rosacea and acne. The use of unique extended-release formulations enables the company to maintain significant pricing power. However, a narrow development profile and dependence on final clinical trials create substantial risks to business sustainability.

Dermata Therapeutics (DRMA) Price to Earnings Ratio: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for Dermata Therapeutics

- price and consensus price forecast:
Stock Price dermatarx.com|DRMA - Consensus Target
- market capitalization information:
Market Value Dermata Therapeutics, Inc.|DRMA - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Share Dermata Therapeutics|DRMA - Company Book Value|Market Capitalization to Book Value Ratio dermatarx.com|DRMA - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital Coefficient Dermata Therapeutics|DRMA - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Dermata Corp|DRMA - Company Aggregate Debts|Debt to Book Value Ratio Dermata Therapeutics, Inc.|DRMA - Company Long-Term Debts|Short-Term Debt Dermata Therapeutics|Intermediate Coverage Ratio dermatarx.com
- earnings and market multiples details:
DRMA - Company Net Income|Future Profit Dermata Therapeutics|DRMA - P/E Multiple|Forward P/E Multiple Dermata Therapeutics Inc|DRMA - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Dermata Therapeutics, Inc.|DRMA - Operating profit EBITDA|Net earnings per share (EPS TTM) Dermata Therapeutics|DRMA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months dermatarx.com|DRMA - Net earnings per share growth this year|Projected earnings per share increase next year Dermata Therapeutics
- sales volume and revenue indicators:
DRMA - Revenue and Sales Volume|Company Future Revenue dermatarx.com|DRMA - P/S Multiple|Market Cap to Future Revenue Ratio Dermata Therapeutics, Inc.
Summary company analysis:dermatarx.com DRMA
Manufactured product of dermatarx.com

The P/E ratio reflects the proportion between the market value of a business and its annual net income. This metric measures the investment payback period through the lens of current earnings. By analyzing P/E fluctuations for Dermata Therapeutics (DRMA) on the GURU.Markets platform, an investor can see how the price depends on the binary risks of clinical trials. A narrow specialization in acne medications makes the multiple extremely volatile. High pipeline uncertainty turns this indicator into a marker of speculative expectations.

Key competitors

P/E Multiple krystalbio.com|Price to Earnings Ratio APGE (Apogee Therapeutics, Inc.)|ARQT (Arcutis) - Company Value to Net Income|Price to Earnings Ratio Vericel Corp. VCEL|Business Payback Period Oruka Pharma (ORKA)|SMTI - Price to Earnings Ratio|DBVT - P/E Multiple|SLSN: P/E Multiple|DERM - Business Payback Period|Price to Earnings Ratio Forte Biosciences, Inc|Price to Earnings Multiple EMPG (Empro Corporation)|P/E Multiple SLGL|reviveprocare.com - Price to Earnings Multiple|P/E Multiple MDCX (Medicus Pharma)|Verrica Pharmaceuticals Inc (VRCA) - Market Cap to Earnings|HOTH - Price to Earnings Ratio|Company Value to Net Income BFRI (Biofrontera Inc.)|vynetherapeutics.com (VYNE) - Price to Earnings Ratio|Price to Earnings Ratio Sonoma Pharmaceuticals, Inc.|QNRX (Quoin Pharmaceuticals Ltd) - P/E Multiple|P/E Multiple Azitra Inc|Price to Earnings Ratio ELAB (Elevai Skincare)|Market Price to Net Income Ratio RVNC